Pharmaceutical Business Development and Licensing


Use this report’s detailed metrics and real-company practices to reinforce your pharmaceutical business development and licensing (BD&L) group to successfully close deals. Benchmark business development and licensing staffing and budgets while exploring structure models to streamline communication and clarify reporting relationships. Find out who should be at the negotiating table — and who shouldn’t — as you master the deal-making process. From deal identification to due diligence to finalization, follow key pointers from leading executives across the industry and watch for the three most common pitfalls. Finally, discover strategies for building solid relationships, resolving conflicts and minimizing the effects of employee turnover.

Download Now! speak-to-an-expert

Report Details

Publication Date: June 2011
Pages: 121
Chapters: 3
Metrics: 400+
Charts/Graphics: 50+

Top Reasons to Buy this Pharmaceutical Business Development Report

Build a Top-Notch Pharmaceutical Business Development and Licensing Team: Explore models of pharmaceutical business development and licensing team structure that bolster communication and streamline reporting relationships. Use detailed benchmarks to discover when other pharma and biotech companies pursue deals — and ensure your pharmaceutical business development team has ample spending and staffing resources.

Maximize Deal Position: Follow strategic recommendations to guarantee a thorough process and a well-negotiated deal. Evaluate prospective partners and see how they’ll evaluate you as you identify red flags and avoid weak deals. See who should be involved in the deal-making process and when — and learn to expertly handle the tough questions that inevitably arise.

Master Post-Deal Management: Examine real-company practices for managing partnerships, with or without a formal alliance management team. Get the right personnel involved at the right points — and build institutional memory that will protect the partnership through personnel turnover and team changes.

You may also be interested in CEIConnect: The Lifesciences Industry’s On-Demand Research Resource as well as our individual portfolio management research reports.

Excerpt from Pharmaceutical Business Development and Licensing

In recent years, R&D pipelines at large pharmaceutical companies have been hit hard due to general clinical problems, increased safety limits imposed by the FDA and changes in market access and prescribing habits. Because the pipeline is the lifeblood of any pharmaceutical company, shareholders are concerned for the health of many Top 50 companies.

On the other end of the spectrum are the smaller pharmaceutical and biotech companies. Most of these companies have been plagued by dry investor channels and limited access to public funding, even though they own clinically promising compounds and therapies with equally promising forecasted revenues. With fewer resources, they cannot afford to continue development or establish a commercial arm in preparation for product launch.